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Provoked vestibulodynia (PVD) is a prevalent genital pain syndrome that has been assumed to be 
chronic, with little spontaneous remission. Despite this assumption, there is a dearth of empirical 
evidence regarding the progression of PVD in a natural setting. Although many treatments are available, 
there is no single treatment that has demonstrated efficacy above others.  
Aims: 
 The aims of this secondary analysis of a prospective study were to (1) assess changes over a two-year 
period in pain, depressive symptoms and sexual outcomes in women with PVD and (2) examine changes 
based on treatment(s) type. 
Main Outcome Measures: 
Visual Analogue Scale of genital pain, Global Measure of Sexual Satisfaction, Female Sexual Function 




239 women with PVD completed both time one and two questionnaires. For the sample as a whole, 
there was significant improvement over two years on pain ratings, sexual satisfaction, sexual function, 
and depressive symptoms. The most commonly received treatments were physical therapy, 
sex/psychotherapy, and medical treatment, although 41.0% did not undergo any treatment. Women 
receiving no treatment also improved significantly on pain ratings. No single treatment type predicted 
better outcome for any variable except depressive symptoms, in which women who underwent surgery 




These results suggest that PVD may significantly reduce in severity over time. Participants demonstrated 
clinically significant pain improvement, even when they did not receive treatment. Furthermore, the 
only single treatment type predicting better outcomes was surgery, and only for depressive symptoms, 
accounting for only 2.3% of the variance. This data does not demonstrate the superiority of any one 
treatment and underscores the need to have control groups in PVD treatment trials, otherwise 
improvements may simply be the result of natural progression.  
Introduction  
Provoked vestibulodynia (PVD) is a genital pain disorder in women characterized by burning and cutting 
pain at the vulvar vestibule. The prevalence rate among women in the general population is estimated 
to be 12%1. Physiological and psychosocial mechanisms such as inflammation, pelvic floor muscle 
dysfunction, pain sensitization2, and maladaptive pain cognitions3 have been suggested to explain 
etiology, however there is no systematic evidence supporting any single pathway. While pain is the 
primary symptom, PVD is also associated with sexual dysfunction and sexual dissatisfaction4. 
Unfortunately, little is known about how PVD progresses over time. The present prospective study, 
carried out over a two-year period, aimed to describe pain, psychosocial, and sexual changes in women 
with PVD. 
Perhaps because there are a number of diverse etiological hypotheses, there are also a wide variety of 
potential treatments for PVD. Common modalities include topical lidocaine, tricyclic antidepressants, 
botox injections, cognitive-behavioral (CBT) sex therapy and pain management, pelvic floor physical 
therapy, vestibulectomy and alternative therapies such as acupuncture5-7. Despite many promising 
preliminary treatment studies, many of these studies lack a control or placebo condition8-10 and post-
treatment follow-ups are generally short. Furthermore, with a few exceptions, treatments are rarely 
compared with one another11,12 and patients typically receive more than one treatment13. The best 
outcome efficacy evidence supports vestibulectomy5,6, although large scale RCTs are lacking. These 
limitations are problematic, as without a control group, outcomes cannot be specifically attributed to 
the treatment being investigated. The present study aimed to examine 2-year outcomes by treatment 
type, as well as for women who did not undergo any treatment. 
Although PVD is generally conceptualized as a chronic condition, there may be significant variation in 
symptoms over time. The few prospective follow-up studies of women with PVD have tended to 
examine only changes in prevalence and incidence over time14,15, rather than change in pain and 
sexuality outcomes. Reed et al.14 have demonstrated a significant change in diagnostic group (PVD to 
non-PVD or vice versa) at two-year follow-up, with 22.2% of those initially classified as PVD going into 
remission. In a second follow-up study with 2 and 4-year follow-ups, it was found that only 44% of the 
women with PVD at year 2 were still classified as PVD cases at year 416. One limitation of this study was 
that diagnosis was made using an online survey. In separate 1-year follow-up study of 72 women with 
PVD at time 1, only 35 reconfirmed (48%) PVD at time 215. However, among those who no longer had 
PVD symptoms, 36 claimed to have never had such symptoms, which makes these findings difficult to 
interpret. Despite their limitations, these studies are important in demonstrating a wide variation in 
long-term outcomes for women with PVD. Unfortunately, none of these longitudinal studies assessed 
whether or not participants received treatment in the interim. Furthermore, women were simply 
classified based on a dichotomous variable; hence little is known about the variation in pain 
symptomatology for women that stay within a diagnosis, nor is anything known about changes in 
psychosocial or sexual variables.  
In order to further document treatment outcomes, better longitudinal data are needed on the natural 
progression of women treated for PVD. Randomized trials have the advantage of providing a controlled 
environment within which to assess treatment efficacy, however, they are limited by their strict 
selection criteria, which may result in a more homogeneous and potentially unrepresentative sample. 
Finally, when assessing long-term outcomes in women with PVD, treatment type needs to be taken into 
account to create a more complete picture of long-term changes.  
Aims 
The overarching aim of this secondary analysis of a prospective, non-treatment study was to assess, over 
a two-year period, changes in pain, psychosocial and sexual outcomes in women with PVD. Based on 
prior empirical evidence, we hypothesized that there would be significant decreases in pain between 
time 1 and time 2 assessments. We also hypothesized that women receiving vestibulectomy would 
report significantly greater pain reductions than women undergoing other treatments or no treatment. 
It was also hypothesized that women receiving multiple treatments would have the best outcomes on 
pain, psychosocial, and sexual variables.  
Methods 
Participants  
Participants were recruited through gynecologists or other health professionals, as well as through 
newspaper and website advertisements. Because these data were drawn from a larger study on women 
with PVD and their partners, all women were required to be in a relationship at time 1. If women 
indicated an interest in the study, they were screened in person or by telephone to determine eligibility. 
The specific inclusion criteria for women with PVD were: a) pain during intercourse that was subjectively 
distressing, occurred on at least 80% of intercourse attempts, and had lasted > 1 year; b) pain limited to 
intercourse and other activities that caused pressure to be exerted on the vulvar vestibule; c) if recruited 
through a gynecologist, severe pain in one or more vestibular locations during the cotton swab test; d) 
married or cohabiting with a partner for at least 6 months. The exclusion criteria were: a) vulvar pain not 
clearly linked to intercourse or pressure to the vestibule; b) presence of major medical or psychiatric 
illness, active infection, deep dyspareunia, vaginismus, dermatologic lesion, pregnancy, age < 18 years 
old or > 45 years old. 
Main outcome measures 
Pain intensity 
Pain intensity was measured using a Visual Analog Scale (VAS) by asking participants to estimate (0-10) 
their average provoked vulvo-vaginal pain over the past month. This measure has good validity and 
reliability in assessing different types of pain17. It has been shown to be sensitive to PVD treatment 
effects18, and correlates well with other measures of pain19.  
Sexual Satisfaction  
The Global Measure of Sexual Satisfaction (GMSEX)20 was used to measure sexual satisfaction. The 
GMSEX is a five-item measure that assesses satisfaction using a 7-point Likert scale. The scale has good 
reliability and excellent validity21. The Cronbach alpha in the present sample was 0.90. 
Sexual Function 
The Female Sexual Function Index (FSFI) is a well-validated measure of sexual function in women 22. The 
FSFI is divided into 6 dimensions: desire, arousal, lubrication, orgasm, sexual satisfaction, and pain. In 
the present study the total score was calculated omitting the pain subscale, in order to separate sexual 
dysfunction from pain. Higher scores indicate better sexual function, and the proposed cutoff for sexual 
dysfunction is 26, but because we did not include the pain subscale, the cutoff for the present sample 
would be 20. The Cronbach alpha for the present sample was 0.78. 
Beck Depression Inventory 
The Beck Depression Inventory (BDI) is a widely used, sensitive, and validated measure of depressive 
symptoms in adults23. Greater scores indicate greater depressive symptoms, with scores from 0-9 
indicating minimal symptoms, 10-18 indicating mild to moderate, and 19 and over indicating moderate 
to severe. The Cronbach alpha in the present study was 0.89. 
Dyadic Adjustment Scale 
The revised Dyadic Adjustment Scale (DAS)24 measures relationship satisfaction, with higher scores 
indicating better satisfaction, and scores under 50 indicating potential distress. The original dyadic 
adjustment scale shows good psychometric properties, and the revised scale is a shorter version that 
shows high correlation with the original24. The Cronbach alpha in the present study was 0.83. 
Sexual behavior 
Participants were asked how many times they had attempted to have sexual intercourse with vaginal 
penetration over the past month. The actual number of attempts, successful or not, was taken as the 
measure of intercourse attempts. 
Procedure 
This study was approved by the _____ Institutional Review Board, and all participants gave written 
informed consent. A research assistant was present at weekly vulvo-vaginal pain clinics. The 
gynecologists told eligible participants about the study, and if they were interested were instructed to 
meet with the research assistant. Women were either given a questionnaire package in person at a 
gynecology clinic or, if recruited via advertisement, the package was sent to their home. Two years later, 
a research assistant contacted each woman who participated at Time 1. If they agreed to participate for 
the follow-up they were sent a package via regular mail and were asked to complete the measures using 
the same instructions as at Time 1. As compensation for their time, women who completed all 
questionnaires at Time 1 were offered a 30-minute telephone consultation with a clinical sexologist, 
focusing on education about vulvo-vaginal pain and its treatment. They were also given information 
about health professionals (physical therapists, gynecologists, and psychologists) working in their area. 
The compensation at Time 2 was 25$ per member of the couple.  
Statistical analyses 
All data was analyzed using SPSS version 20 (IBM corporation, USA). At the second time point, each 
participant was asked whether they had engaged in any type of treatment over the past 24 months. If 
they reported yes, they were given a checklist with the following options: physical therapy, sex 
therapy/psychotherapy, medical management, surgery, acupuncture, or other. Pearson’s r was used to 
examine correlations between demographics and variables of interest. Paired samples t-tests were used 
to examine the changes between T1 and T2 for the entire sample. Following this, the entire sample was 
split by treatment type, and paired samples t-tests were used to compare outcome variables within 
these groups. Finally, six multiple regression analyses were conducted using change in pain, sexual 
function, sexual satisfaction, dyadic adjustment, attempts at intercourse, and depressive symptoms as 
the outcome variables. A change score was calculated for each outcome by subtracting T1 scores from 
T2 scores. A separate multiple regression analysis was conducted for each outcome variable. To control 
for T1 variables, T1 pain was entered in the first block, followed by all other T1 variables in the second 
block, and treatment type entered into the third block. 
Results 
Sample characteristics 
A total of 354 participants completed the questionnaires at Time 1 (T1), and 239 at Time 2 (T2), for a 
retention rate of 67.5%. Reasons for not completing T2 included not being able to re-contact or lack of 
interest in participating. Therefore, the final data analyzed included 239 women. Using independent 
samples t-tests, there were no significant differences (p > 0.05) on T1 variables, age or pain duration 
between women who completed and women who did not complete T2. Pain VAS scores at T1 in the 
present sample were similar to previous studies of women with PVD, which range from 6.9-7.5/1012,19,25 
Of these 239 women, 117 had been diagnosed with PVD by their gynecologist, and the remainder (122) 
met criteria for PVD-like symptoms based on the telephone screening. Other than age, there were no 
significant differences on any demographic, T1, or change variables between women who had been 
diagnosed by a gynecologist, and those that had not. Women who had been diagnosed by a gynecologist 
were significantly younger (28.7 vs. 33.1, t = 3.11, p < 0.01) The mean age of the sample at T1 was 30.9 
years (range = 18-68, SD = 10.9). The mean pain duration at T1 was 5.5 years (range = 0.5 – 43.8, SD = 
6.0), and the mean pain intensity was 6.9/10 (range = 1-10, SD – 1.9). There were no significant 
differences in pain duration between treatment types, although women who underwent surgery had 
significantly higher pain intensity at T1 compared to all other groups combined (t = 1.92, p < 0.05), and 
those who reported taking part in “other” treatment(s) had significantly lower pain intensity at T1 
compared to all other groups combined (t = 1.14, p < 0.05) (see table 2 for means). All women were in a 
relationship at T1 and the mean relationship duration was 6.9 years (range = 0.5-38.4, SD = 7.6). At T2, 
188 (80%) remained in the same relationship, 26 (11.1%) were with a new partner, and 21 (8.9%) were 
now single. Using one-way ANOVA with tukey’s HSD, the only difference on any T1 variable was for T1 
DAS, in which women who had a new partner at T2, had significantly lower relationship satisfaction at 
T1 (F = 3.15, p < 0.05). The majority (94.1%) identified culturally as XXXXX or XXXX (blinded for review), 
and had at least completed high school (95.3%). The number of women who had engaged in the 
different treatment types is included in Table 1, with physical therapy being the most common 
treatment. 
Group changes 
There were no significant associations between demographic variables or pain duration with change 
variables. On the whole, using paired samples t-tests, there were general improvements on four out of 
six outcome variables between T1 and T2 (see Table 2). Pain (Δ-2.8) and depressive symptoms (Δ-2.4) 
were significantly lower, while sexual function (Δ+1.4)  and sexual satisfaction (Δ+1.8) significantly 
increased. The only variables that did not significantly change were number of attempts at intercourse 
over the past month and dyadic adjustment, although the scores for the dyadic adjustment scale were 
within the non-distressed norms at both time points24.  
Changes based on treatment type 
Differences between T1 and T2 variables were also examined within each treatment type (Table 2) using 
a significance level of p < 0.01 to control for multiple comparisons. For all treatments except 
acupuncture, there was a significant reduction in pain. There was also a significant reduction in pain for 
those receiving no treatment. None of the treatment groups showed significant changes in number of 
attempts at intercourse or relationship satisfaction. Changes in sexual function, depressive symptoms, 
and sexual satisfaction varied with treatment type (see Table 2), although tended to generally improve. 
Using norm-based scores, for DAS, all groups were in the healthy range at T1 and T2. For FSFI, all groups 
were in dysfunctional range at T1 and only the other-treatment group was in the functional range at T2. 
For BDI, all groups were in the mild group at T1, and all groups were in the minimal range at T2 except 
for the no-treatment group, which remained in the mild range. 
Treatment comparison 
Six hierarchical regression models were tested, one for each of the outcome variables. After controlling 
for T1 variables, no treatment type was a significant predictor of any outcome except depressive 
symptoms. In the model predicting change in depressive symptoms, the first step (T1 pain) was not 
significant (F = 0.08, p = 0.773) and explained 0.5% of the variance. The second step, adding T1 variables, 
provided a significant F-change (F = 12.68, p < 0.001) and explained an additional 27.5% of the variance. 
The significant predictors of change in depressive symptoms were T1 FSFI, T1 DAS, and T1 depressive 
symptoms. The third step, adding treatment types, provided a significant F-change (F = 6.61, p < 0.01), 
and explained an additional 2.3% of the variance. The only significant predictor of change in depressive 
symptoms at this last step was surgery (β = -0.169, p < 0.05).  
Discussion 
The most remarkable finding of the present study is that women with PVD generally improved over two 
years on pain, psychosocial, and sexuality outcomes. On the other hand, no significant changes were 
found for any group on dyadic adjustment or number of attempts at intercourse, despite improvements 
in pain. When examining outcomes based on treatment type, results showed that all treatments except 
acupuncture were associated with significantly lower pain levels at T2, including the ‘no treatment’ 
group. Equally striking is the fact that 41% of study participants did not receive any treatment over the 
two-year period despite being motivated enough to take part in research.  
An examination of the entire sample indicated that there was a statistically significant change on all 
outcome variables with the exception of dyadic adjustment and number of attempts at intercourse. 
Although statistical change is important, it does not necessarily imply clinical relevance. The IMMPACT 
recommendations for clinical trials in chronic pain state that changes in perceived pain intensity from 
baseline of 10-20% or 1/10 reflect minimal change, while changes >30% or 2/10 represent at least 
moderately important clinical differences26. Based on these recommendations, the changes in the 
present sample do reflect a clinically significant change. IMMPACT recommendations are also made for 
depressive symptoms (BDI scores), indicating that scores that begin over 10 and are reduced to <10 at 
follow-up are clinically significant26. Again, the present data indicate that these criteria are met for all 
groups except the no treatment group, leading us to conclude that women with PVD as a whole showed 
clinically significant changes in pain over a two-year period, even if they did not undergo treatment, 
while all groups except the no treatment group had clinically significant reductions in depressive 
symptoms. The IMMPACT guidelines do not make recommendations regarding sexual function, but 
despite improvements on the FSFI, scores were still in the dysfunctional range at T2. 
It was also remarkable that women who did not take part in any treatment over the two-year period 
reported statistically significant reductions in pain that would be considered clinically significant based 
on IMMPACT guidelines. This is important information for treatment trials, as the majority of trials in 
PVD do not have a control group5. Considering that there appears to be a significant improvement in 
pain over time without treatment, it is imperative that randomized trials yield an improvement above 
and beyond what appears to be the natural progression of PVD. Indeed, in the present sample, when 
treatment type was used to predict change in outcome variables, after controlling for pre-treatment 
levels of all outcomes, only surgery predicted any outcome, which was depressive symptoms, and all 
treatment types only accounted for 2.3% of the variance. It is also important to note that, other than for 
two women, all women undergoing surgery had also had other treatment, hence one cannot necessarily 
attribute these changes to surgery alone. On the other hand, these also likely represent women for 
whom other conservative treatments have not worked, and thus may represent a group of particularly 
difficult PVD. Furthermore, this was not a randomized trial, hence women underwent treatments based 
on their own volition and may have been influenced by their status at Time 1. Indeed, women who 
underwent surgery had the greatest reductions in pain, but also had higher levels of pain initially, and 
this change was not significant after controlling for T1 variable. This may indicate a source of selection 
bias in non-randomized treatment trials. Overall, type of treatment accounted for very little variance in 
the models of change (<5%), suggesting that no single modality appears superior to any other. Finally, T1 
variables accounted for much more of the variance than treatment type. This may indicate a wide 
variation initial variable levels that should be taken into account when assessing treatments, both in a 
clinical and research setting.  
There were also certain psychosexual outcomes that did not improve, despite pain improvement. This is 
particularly the case for the no treatment group, which did not have any significant improvement on any 
variables except pain. For all groups, number of attempts at intercourse did not change significantly, 
despite improvements in pain and other psychosocial variables. In addition, although there was a 
significant improvement in sexual function, average scores were still below the recommended cut-off on 
the FSFI for sexual dysfunction22. Despite low sexual function, dyadic adjustment did not change, but 
was within healthy norms at both time points.  It is tempting to assume that when the pain is reduced, 
there will be a commensurate improvement in psychosexual variables, but this was often not the case. 
While pain reduction is an important goal in treatment of PVD, once the pain is reduced, further 
treatment tailored to the individual or couple may be needed to improve other aspects of quality of life. 
This may be a way in which some of the treatments outperform the no treatment group, as the no 
treatment group did not improve significantly on any psychosexual measures, while other treatment 
groups did. This suggests that better targeted interventions may need to be developed. Finally, this 
highlights the need to assess more than pain in PVD treatment trials, as other important variables may 
not improve, even when pain does. 
The present study provides interesting data on treatment preferences, although women may have been 
biased because they were provided with information about treatment options. In general, women who 
were referred by gynecologists were more likely to engage in treatments of all type except acupuncture 
(table 1). This may reflect both an interest in treatment, as they were already being followed as well 
more options provided by their health care provider. The most common treatment by far was PT 
(41.0%), followed by sex therapy/psychotherapy (19.2%) and medical management (18.8%). These are 
likely perceived as low risk treatments, hence are more popular. Surgery was not common, and in all 
cases except two, was combined with some other type of treatment. This may reflect the choice of 
surgery as a last resort. Of particular interest is the number of women who did not undergo treatment 
(41%), which is consistent with previous studies1. This high number is in spite of being given a list of 
treatment providers in the area, and many having been referred to the study by a gynecologist. In 
addition, it is not clear whether this represents the treatment preferences of the patient, or the 
provider. 
These results make it difficult to draw clear conclusions about the natural progression of PVD. On the 
positive side, PVD pain appears to lessen in severity over time. On the negative side, it is not clear what 
the best treatment options are. Without randomization of treatments and careful controls, it is 
impossible to make clear conclusions about treatment effectiveness. Considering the potential for 
adverse outcomes, it remains important to continue to search for lower impact treatments. Empirical 
validation of the efficacy of each treatment type will need to be provided in the form of randomized, 
placebo-controlled trials before a gold-standard treatment strategy can be developed. 
There are a number of limitations to the present study. First, due to this sample being part of a larger 
study, all women were in a heterosexual relationship. It is not known whether the present results would 
generalize to a sample of non-partnered or non-heterosexual women. Indeed, being in a stable and 
supportive relationship may have an impact on PVD over time27. Nonetheless, women in this group did 
appear to be within the pain range of other studies on this population. Second, this study was not 
designed as a treatment trial, hence there is likely a treatment selection bias.  Furthermore, treatments 
were divided into simple categories and the specific details of the treatments are not known, nor are the 
lengths of treatments. Therefore, there could be significant differences between the treatments 
received by two people in the same category, whether in duration or in the type of modalities used. In 
addition, treatments that women received that were not for PVD, but may have had a secondary effect 
on PVD were not assessed. Another limitation is that this sample was comprised of a majority of 
participants who sought out and took part in some form of treatment. However, considering that only 
60% of women in the general vulvodynia population are thought to actually receive treatment1, our 
sample, of which 59% sought treatment, appears to be representative in terms of treatment-seeking 
patterns. Another bias may stem from the simple fact of taking part in a study and receiving attention 
from a skilled health professional in the form of an educational telephone consultation. This may have 
also influenced the treatments that women chose. In addition, not all women were diagnosed with PVD 
by a physician, but instead met criteria over a telephone screening form, hence could only be said to 
have “PVD-like symptoms.” It would have improved the study to have women assessed at Times 1 and 2 
by a physician.  
Conclusion 
The course of PVD appears to reduce in severity over time. As a whole, women with PVD tend to 
improve on pain, whether they receive treatment or not, however some treatment appear to confer 
better outcomes on psychosexual variables. The present findings did not provide clear evidence in 
support of the superiority of any one treatment, and highlight the need for randomized, placebo-
controlled trials that compare treatments in the future. 
 
1. BL H, EG S. A population-based assessment of chronic unexplained vulvar pain: have we 
underestimated the prevalence of vulvodynia? J Am Med Womens Assoc. 2003;58:82–88. 
2. Bergeron S, Rosen NO, Morin M. Genital pain in women: Beyond interference with intercourse. Pain. 
2011;152:1223–1225.  
3. Dewitte M, Van Lankveld J, Crombez G. Understanding sexual pain: A cognitive-motivational account. 
Pain. 2011;152:251–253.  
4. Desrochers G, Bergeron S, Landry T, Jodoin M. Do psychosexual factors play a role in the etiology of 
provoked vestibulodynia? A critical review. J Sex Marital Ther. 2008;34:198–226.  
5. Andrews JC. Vulvodynia interventions—Systematic review and evidence grading. Obstet Gynecol Surv. 
2011;66:299–315.  
6. Landry T, Bergeron S, Dupuis M-J, Desrochers G. The treatment of provoked vestibulodynia. The Clin J 
Pain. 2008;24:155–171.  
7. Fugl-Meyer KS, Bohm-Starke N, Damsted Petersen C, Fugl-Meyer A, Parish S, Giraldi A. Standard 
Operating Procedures for Female Genital Sexual Pain. J Sex Med. 2012;10(1):83–93.  
8. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-A novel treatment for 
provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex 
Med. 2009;6:2523–2537.  
9. Foster DC, Kotok MB, Huang LS, Watts A. Oral desipramine and topical lidocaine for vulvodynia: A 
randomized controlled trial. Obstet Gynecol. 2010; 116: 583-593. 
10. Nyirjesy P. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo 
controlled study. S Transm Infec. 2001;77:53–57.  
11. Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical 
lidocaine gel: A randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet 
Gynecol Scand. 2006;85:1360–1367.  
12. Bergeron S, Binik YM, Khalife S, et al. A randomized comparison of group cognitive–behavioral 
therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia 
resulting from vulvar vestibulitis. Pain. 2001;91:297–306.  
13. Updike GM, Wiesenfeld HC. Insight into the treatment of vulvar pain: A survey of clinicians. Am J 
Obstet Gynecol. 2005;193:1404–1409.  
14. Reed BD, Haefner HK, Sen A, Gorenflo DW. Vulvodynia incidence and remission rates among adult 
women. Obstet Gynecol. 2008;112:231–237.  
15. Sutton JT, Bachmann GA, Arnold LD, Rhoads GG, Rosen RC. Assessment of vulvodynia symptoms in a 
sample of U.S. women: A follow-up national incidence survey. J Womens Health. 2008;17:1285–1292.  
16. Reed BD, Payne CM, Harlow SD, Legocki LJ, Haefner HK, Sen A. Urogenital symptoms and pain history 
as precursors of vulvodynia: A longitudinal study. J Womens Health. 2012;21:1139–1143.  
17. Turk DC, Melzack R. Handbook of Pain Assessment, Third Edition. Guilford Publications: 2010. 
18. Bergeron S, Khalife S, Glazer HI, Binik YM. Surgical and behavioral treatments for vestibulodynia. 
Obstet Gynecol. 2008;111:159–166.  
19. Desrochers G, Bergeron S, Khalifé S, Dupuis MJ, Jodoin M. Fear avoidance and self-efficacy in relation 
to pain and sexual impairment in women with provoked vestibulodynia. Clin J Pain. 2009;25:520–527. 
20. Lawrance K, Byers ES. Interpersonal exchange model of sexual satisfaction questionnaire. Sexuality 
related measures: A Compendium. 1998;2:514-519. 
21. Byers ES, Macneil S. Further validation of the interpersonal exchange model of sexual satisfaction. J 
Sex Marital Ther. 2006;32:53–69.  
22. Rosen C Brown J Heiman S Leib R. The female sexual function index (FSFI): A multidimensional self-
report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.  
23. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-
five years of evaluation. Clin Psychol Rev. 1988;8:77-100. 
24. Busby DM, Christensen C, Crane DR. A revision of the dyadic adjustment scale for use with distressed 
and nondistressed couples: Construct hierarchy and multidimensional scales. J Marital Fam Therapy. 
2007;21:289-308. 
25. Zolnoun D. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obst & Gyn. 
2003;102(1):84–87.  
26. Dworkin RH, Turk DC, McDermott MP. Interpreting the clinical importance of group differences in 
chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238-244. 
27. Rosen NO, Bergeron S, Glowacka M, Delisle I, Baxter ML. Harmful or Helpful: Perceived Solicitous 
and Facilitative Partner Responses Are Differentially Associated with Pain and Sexual Satisfaction in 
Women with Provoked Vestibulodynia. J Sex Med. 2012;9(9):2351–2360.  
 
